Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Bone marrow blast elimination by the fifth day of 7 + 3 induction is the strongest predictor of potential cure in patients with acute myeloid leukemia younger than 61 years of age: A long-term follow-up of a multi-center prospective study.

Ofran Y, Hayun M, Leiba R, Zuckerman T, Horowitz N, Hoffman R, Ringelstein S, Lavi N, Frisch A, Henig I, Gatt ME, Hellmann I, Arad A, Bulvik S, Ram R, Gino-Moor S, Saban R, Tvito A, Rowe JM, Ganzel C.

Am J Hematol. 2019 Oct 7. doi: 10.1002/ajh.25651. [Epub ahead of print] No abstract available.

PMID:
31591736
2.

How I diagnose and manage Philadelphia chromosome-like acute lymphoblastic leukemia.

Frisch A, Ofran Y.

Haematologica. 2019 Nov;104(11):2135-2143. doi: 10.3324/haematol.2018.207506. Epub 2019 Oct 3. Review.

3.

Anti-herpesvirus prophylaxis, pre-emptive treatment or no treatment in adults undergoing allogeneic transplant for haematological disease: systematic review and meta-analysis.

Beyar-Katz O, Bitterman R, Zuckerman T, Ofran Y, Yahav D, Paul M.

Clin Microbiol Infect. 2019 Sep 16. pii: S1198-743X(19)30488-4. doi: 10.1016/j.cmi.2019.09.003. [Epub ahead of print] Review.

PMID:
31536817
4.

Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remission-a multi-center historical control study.

Berger T, Rozovski U, Moshe Y, Yaari S, Frisch A, Hellmann I, Apel A, Aviram A, Koren-Michowitz M, Yeshurun M, Ram R, Raanani P, Ofran Y, Wolach O.

Ann Hematol. 2019 Sep 11. doi: 10.1007/s00277-019-03795-8. [Epub ahead of print]

PMID:
31512015
5.

Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia.

Ofran Y, Ringelstein-Harlev S, Slouzkey I, Zuckerman T, Yehudai-Ofir D, Henig I, Beyar-Katz O, Hayun M, Frisch A.

Leukemia. 2019 Aug 21. doi: 10.1038/s41375-019-0548-z. [Epub ahead of print] No abstract available.

PMID:
31435023
6.

Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation.

Beyar-Katz O, Lavi N, Ringelstein-Harlev S, Henig I, Yehudai-Ofir D, Haddad N, Fineman R, Ofran Y, Nov Y, Sahar D, Moustafa-Hawash N, Rowe JM, Zuckerman T.

Leuk Lymphoma. 2019 Oct;60(10):2449-2456. doi: 10.1080/10428194.2019.1594214. Epub 2019 Apr 3.

PMID:
30943060
7.

The role of specialized hospital units in infection and mortality risk reduction among patients with hematological cancers.

Carmen R, Yom-Tov GB, Van Nieuwenhuyse I, Foubert B, Ofran Y.

PLoS One. 2019 Mar 20;14(3):e0211694. doi: 10.1371/journal.pone.0211694. eCollection 2019.

8.

Homozygosity for CHEK2 p.Gly167Arg leads to a unique cancer syndrome with multiple complex chromosomal translocations in peripheral blood karyotype.

Paperna T, Sharon-Shwartzman N, Kurolap A, Goldberg Y, Moustafa N, Carasso Y, Feinstien M, Mory A, Reznick-Levi G, Gonzaga-Jauregui C, Shuldiner AR, Basel-Salmon L, Ofran Y, Half EE, Baris Feldman H.

J Med Genet. 2019 Mar 11. pii: jmedgenet-2018-105824. doi: 10.1136/jmedgenet-2018-105824. [Epub ahead of print]

PMID:
30858171
9.

Baseline Chest Computed Tomography for Early Diagnosis of Invasive Pulmonary Aspergillosis in Hemato-oncological Patients: A Prospective Cohort Study.

Bitterman R, Hardak E, Raines M, Stern A, Zuckerman T, Ofran Y, Lavi N, Guralnik L, Frisch A, Nudelman O, Paul M, Oren I.

Clin Infect Dis. 2019 Oct 30;69(10):1805-1808. doi: 10.1093/cid/ciz194.

PMID:
30855077
10.

Palliative care service incorporated in a hematology department: a working model fostering changes in clinical practice.

Ofran Y, Bar-Sela G, Toledano M, Kushnir I, Moalem B, Gil W, Kazman N, Fineman R.

Leuk Lymphoma. 2019 Aug;60(8):2079-2081. doi: 10.1080/10428194.2018.1564826. Epub 2019 Jan 25. No abstract available.

PMID:
30681028
11.

Computational Design of Epitope-Specific Functional Antibodies.

Nimrod G, Fischman S, Austin M, Herman A, Keyes F, Leiderman O, Hargreaves D, Strajbl M, Breed J, Klompus S, Minton K, Spooner J, Buchanan A, Vaughan TJ, Ofran Y.

Cell Rep. 2018 Nov 20;25(8):2121-2131.e5. doi: 10.1016/j.celrep.2018.10.081.

12.

Computational design of antibodies.

Fischman S, Ofran Y.

Curr Opin Struct Biol. 2018 Aug;51:156-162. doi: 10.1016/j.sbi.2018.04.007. Epub 2018 May 20. Review.

PMID:
29791878
13.

Characteristics of ataxic gait in familial dysautonomia patients.

Portnoy S, Maayan C, Tsenter J, Ofran Y, Goldman V, Hiller N, Karniel N, Schwartz I.

PLoS One. 2018 Apr 26;13(4):e0196599. doi: 10.1371/journal.pone.0196599. eCollection 2018.

14.
15.

A novel Fer/FerT targeting compound selectively evokes metabolic stress and necrotic death in malignant cells.

Elkis Y, Cohen M, Yaffe E, Satmary-Tusk S, Feldman T, Hikri E, Nyska A, Feiglin A, Ofran Y, Shpungin S, Nir U.

Nat Commun. 2017 Oct 16;8(1):940. doi: 10.1038/s41467-017-00832-w.

16.

Grb2 regulates the proliferation of hematopoietic stem and progenitors cells.

Frelin C, Ofran Y, Ruston J, Hayun M, Derdikman Y, Khier Y, Rozales K, Brenner B, Iscove N, Pawson T, Louria-Hayon I.

Biochim Biophys Acta Mol Cell Res. 2017 Dec;1864(12):2449-2459. doi: 10.1016/j.bbamcr.2017.09.018. Epub 2017 Sep 28.

17.

Activated kinases in ALL: time to act.

Ofran Y.

Blood. 2017 Jun 22;129(25):3280-3282. doi: 10.1182/blood-2017-05-780015. No abstract available.

PMID:
28642359
18.

Working toward precision medicine: Predicting phenotypes from exomes in the Critical Assessment of Genome Interpretation (CAGI) challenges.

Daneshjou R, Wang Y, Bromberg Y, Bovo S, Martelli PL, Babbi G, Lena PD, Casadio R, Edwards M, Gifford D, Jones DT, Sundaram L, Bhat RR, Li X, Pal LR, Kundu K, Yin Y, Moult J, Jiang Y, Pejaver V, Pagel KA, Li B, Mooney SD, Radivojac P, Shah S, Carraro M, Gasparini A, Leonardi E, Giollo M, Ferrari C, Tosatto SCE, Bachar E, Azaria JR, Ofran Y, Unger R, Niroula A, Vihinen M, Chang B, Wang MH, Franke A, Petersen BS, Pirooznia M, Zandi P, McCombie R, Potash JB, Altman RB, Klein TE, Hoskins RA, Repo S, Brenner SE, Morgan AA.

Hum Mutat. 2017 Sep;38(9):1182-1192. doi: 10.1002/humu.23280. Epub 2017 Jul 7.

19.

The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults.

Litzow MR, Fielding AK, Luger SM, Paietta E, Ofran Y, Rowe JM, Goldstone AH, Tallman MS, Lazarus HM.

Bone Marrow Transplant. 2017 Dec;52(12):1592-1598. doi: 10.1038/bmt.2017.110. Epub 2017 Jun 5. Review.

PMID:
28581459
20.
21.

Second line azacitidine for elderly or infirmed patients with acute myeloid leukemia (AML) not eligible for allogeneic hematopoietic cell transplantation-a retrospective national multicenter study.

Ram R, Gatt M, Merkel D, Helman I, Inbar T, Nagler A, Avivi I, Ofran Y.

Ann Hematol. 2017 Apr;96(4):575-579. doi: 10.1007/s00277-016-2914-5. Epub 2017 Jan 5.

PMID:
28058490
22.

De-novo protein function prediction using DNA binding and RNA binding proteins as a test case.

Peled S, Leiderman O, Charar R, Efroni G, Shav-Tal Y, Ofran Y.

Nat Commun. 2016 Nov 21;7:13424. doi: 10.1038/ncomms13424.

23.

BCR-ABL (Ph)-like acute leukemia-Pathogenesis, diagnosis and therapeutic options.

Ofran Y, Izraeli S.

Blood Rev. 2017 Mar;31(2):11-16. doi: 10.1016/j.blre.2016.09.001. Epub 2016 Sep 16. Review.

PMID:
27665024
24.

Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.

Mittelman M, Filanovsky K, Ofran Y, Rosenbaum H, Raanani P, Braester A, Goldschmidt N, Kirgner I, Herishanu Y, Perri C, Ellis M, Oster HS; Israel Myelodysplastic Syndrome Working Group (MDS-WG).

Ann Hematol. 2016 Oct;95(11):1811-8. doi: 10.1007/s00277-016-2776-x. Epub 2016 Aug 22.

PMID:
27546027
25.

How far from the SNP may the causative genes be?

Brodie A, Azaria JR, Ofran Y.

Nucleic Acids Res. 2016 Jul 27;44(13):6046-54. doi: 10.1093/nar/gkw500. Epub 2016 Jun 6.

26.

How I treat acute myeloid leukemia presenting with preexisting comorbidities.

Ofran Y, Tallman MS, Rowe JM.

Blood. 2016 Jul 28;128(4):488-96. doi: 10.1182/blood-2016-01-635060. Epub 2016 May 27. Review.

27.

How many cycles of 7+3 and for whom?

Ofran Y, Rowe JM.

Leukemia. 2016 Aug;30(8):1796-7. doi: 10.1038/leu.2016.86. Epub 2016 May 13. No abstract available.

PMID:
27174493
28.

Nephrotic syndrome after hematopoietic stem cell transplantation: a single center experience.

Beyar Katz O, Kruzel Davila E, Zuckerman T, Fineman R, Haddad N, Okasha D, Henig I, Rowe JM, Ofran Y.

Minerva Med. 2015 Dec;106(6):355-7. No abstract available.

PMID:
26787650
29.

Adult Nephrotic Syndrome after Hematopoietic Stem Cell Transplantation: Renal Pathology is the Best Predictor of Response to Therapy.

Beyar-Katz O, Davila EK, Zuckerman T, Fineman R, Haddad N, Okasha D, Henig I, Leiba R, Rowe JM, Ofran Y.

Biol Blood Marrow Transplant. 2016 Jun;22(6):975-981. doi: 10.1016/j.bbmt.2015.12.014. Epub 2015 Dec 29. Review.

30.

Is the D14 bone marrow in acute myeloid leukemia still the gold standard?

Ofran Y.

Curr Opin Hematol. 2016 Mar;23(2):108-14. doi: 10.1097/MOH.0000000000000214. Review.

PMID:
26717195
31.

Understanding differences between synthetic and natural antibodies can help improve antibody engineering.

Burkovitz A, Ofran Y.

MAbs. 2016;8(2):278-87. doi: 10.1080/19420862.2015.1123365. Epub 2015 Dec 14.

32.

Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the "3 + 7" induction regimen for acute myeloid leukemia.

Ofran Y, Leiba R, Ganzel C, Saban R, Gatt M, Ram R, Arad A, Bulvik S, Hellmann I, Gino-Moor S, Zuckerman T, Hoffman R, Horowitz N, Lavi N, Ringelstein S, Henig I, Hayun M, Rowe JM.

Am J Hematol. 2015 Dec;90(12):1159-64. doi: 10.1002/ajh.24207. Epub 2015 Nov 17.

33.

Mortality burden related to infection with carbapenem-resistant Gram-negative bacteria among haematological cancer patients: a retrospective cohort study.

Andria N, Henig O, Kotler O, Domchenko A, Oren I, Zuckerman T, Ofran Y, Fraser D, Paul M.

J Antimicrob Chemother. 2015 Nov;70(11):3146-53. doi: 10.1093/jac/dkv218. Epub 2015 Jul 24.

PMID:
26209312
34.

Antibody specific epitope prediction-emergence of a new paradigm.

Sela-Culang I, Ofran Y, Peters B.

Curr Opin Virol. 2015 Apr;11:98-102. doi: 10.1016/j.coviro.2015.03.012. Epub 2015 Mar 31. Review.

35.

Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome.

Ofran Y, Filanovsky K, Gafter-Gvili A, Vidal L, Aviv A, Gatt ME, Silbershatz I, Herishanu Y, Arad A, Tadmor T, Dally N, Nemets A, Rouvio O, Ronson A, Herzog-Tzarfati K, Akria L, Braester A, Hellmann I, Yeganeh S, Nagler A, Leiba R, Mittelman M, Merkel D.

Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):e95-9. doi: 10.1016/j.clml.2015.02.030. Epub 2015 Mar 5.

PMID:
25819366
36.

Interpreting outcome data in hematopoietic cell transplantation for leukemia: tackling common biases.

Ofran Y, Lazarus HM, Rapoport AP, Rowe JM.

Bone Marrow Transplant. 2015 Mar;50(3):324-33. doi: 10.1038/bmt.2014.270. Epub 2015 Jan 12. Review.

PMID:
25581409
37.

Introducing minimal residual disease in acute myeloid leukemia.

Ofran Y, Rowe JM.

Curr Opin Hematol. 2015 Mar;22(2):139-45. doi: 10.1097/MOH.0000000000000113. Review.

PMID:
25575038
38.

PEASE: predicting B-cell epitopes utilizing antibody sequence.

Sela-Culang I, Ashkenazi S, Peters B, Ofran Y.

Bioinformatics. 2015 Apr 15;31(8):1313-5. doi: 10.1093/bioinformatics/btu790. Epub 2014 Nov 27.

PMID:
25432167
39.

Genetic stratification in myeloid diseases: from risk assessment to clinical decision support tool.

Ofran Y.

Rambam Maimonides Med J. 2014 Oct 29;5(4):e0025. doi: 10.5041/RMMJ.10159. eCollection 2014 Oct.

40.

Concealed dagger in FLT3/ITD+ AML.

Ofran Y.

Blood. 2014 Oct 9;124(15):2317-9. doi: 10.1182/blood-2014-09-597690.

PMID:
25301331
41.

Acute myeloid leukemia in adolescents and young adults: challenging aspects.

Ofran Y, Rowe JM.

Acta Haematol. 2014;132(3-4):292-7. doi: 10.1159/000360200. Epub 2014 Sep 10. Review.

PMID:
25228554
42.

Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein.

Kaever T, Meng X, Matho MH, Schlossman A, Li S, Sela-Culang I, Ofran Y, Buller M, Crump RW, Parker S, Frazier A, Crotty S, Zajonc DM, Peters B, Xiang Y.

J Virol. 2014 Oct;88(19):11339-55. doi: 10.1128/JVI.01491-14. Epub 2014 Jul 16.

43.

Large scale analysis of phenotype-pathway relationships based on GWAS results.

Brodie A, Tovia-Brodie O, Ofran Y.

PLoS One. 2014 Jul 9;9(7):e100887. doi: 10.1371/journal.pone.0100887. eCollection 2014.

44.

Using a combined computational-experimental approach to predict antibody-specific B cell epitopes.

Sela-Culang I, Benhnia MR, Matho MH, Kaever T, Maybeno M, Schlossman A, Nimrod G, Li S, Xiang Y, Zajonc D, Crotty S, Ofran Y, Peters B.

Structure. 2014 Apr 8;22(4):646-57. doi: 10.1016/j.str.2014.02.003. Epub 2014 Mar 13.

45.

Co-expression and co-localization of hub proteins and their partners are encoded in protein sequence.

Feiglin A, Ashkenazi S, Schlessinger A, Rost B, Ofran Y.

Mol Biosyst. 2014 Apr;10(4):787-94. doi: 10.1039/c3mb70411d. Epub 2014 Jan 23.

PMID:
24457447
46.

Large-scale analysis of somatic hypermutations in antibodies reveals which structural regions, positions and amino acids are modified to improve affinity.

Burkovitz A, Sela-Culang I, Ofran Y.

FEBS J. 2014 Jan;281(1):306-19. doi: 10.1111/febs.12597. Epub 2013 Nov 26.

47.

Eradication of carbapenem-resistant Enterobacteriaceae gastrointestinal colonization with nonabsorbable oral antibiotic treatment: A prospective controlled trial.

Oren I, Sprecher H, Finkelstein R, Hadad S, Neuberger A, Hussein K, Raz-Pasteur A, Lavi N, Saad E, Henig I, Horowitz N, Avivi I, Benyamini N, Fineman R, Ofran Y, Haddad N, Rowe JM, Zuckerman T.

Am J Infect Control. 2013 Dec;41(12):1167-72. doi: 10.1016/j.ajic.2013.04.018.

PMID:
24274912
48.

Late diagnosis of spinal dural arteriovenous fistulas resulting in severe lower-extremity weakness: a case series.

Iovtchev I, Hiller N, Ofran Y, Schwartz I, Cohen J, Rubin SA, Meiner Z.

Spine J. 2015 Jun 1;15(6):e39-44. doi: 10.1016/j.spinee.2013.08.029. Epub 2013 Oct 2.

PMID:
24246747
49.

The structural basis of antibody-antigen recognition.

Sela-Culang I, Kunik V, Ofran Y.

Front Immunol. 2013 Oct 8;4:302. doi: 10.3389/fimmu.2013.00302. Review.

50.

Correlation between time to diagnosis and rehabilitation outcomes in patients with spinal dural arteriovenous fistula.

Ofran Y, Yovchev I, Hiller N, Cohen J, Rubin SA, Schwartz I, Meiner Z.

J Spinal Cord Med. 2013 May;36(3):200-6. doi: 10.1179/2045772312Y.0000000029.

Supplemental Content

Support Center